Education
About Us
Working with TipRanks
Follow Us
Adlai Nortye Ltd. Sponsored ADR (ANL)
NASDAQ:ANL
RESEARCH TOOLSreports
ANL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.85 - $17.48
Previous Close$2.1
Volume23.09K
Average Volume (3M)6.66K
Market Cap
$71.59M
Enterprise ValueN/A
Total Cash (Recent Filing)$91.49M
Total Debt (Recent Filing)$30.83M
Price to Earnings (P/E)―
Beta1.76
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding93,710,810
10 Day Avg. Volume5,722
30 Day Avg. Volume6,661
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.31
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside363.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Adlai Nortye Ltd. Sponsored ADR News
PremiumCompany Announcements
Adlai Nortye Announces Change in Auditing Firm
PremiumCompany Announcements
Adlai Nortye Announces CFO Transition with Interim Appointment
PremiumCompany Announcements
Adlai Nortye Reports Strong 2024 Mid-Year Results
PremiumCompany Announcements
Adlai Nortye Announces Executive Leadership Transition---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsAN4005 delivers promising safety and preliminary efficacy with Phase 1 update.
Competitive AdvantageThe small-molecule PD-L1 inhibitor space is underdeveloped with no drug approved, providing an opportunity for AN4005 to advance.
Investor SentimentAdlai Nortye has two important upcoming data catalysts, which should fuel positive investor sentiment and bolster the company's growing global footprint.
Bears Say
Market CompetitionThere are several oral small molecules PD-L1 candidates in early development stages, leaving the playing field open for AN4005 to advance.
---
Ownership Overview
―
Insiders
―
Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ANL FAQ
What was Adlai Nortye Ltd. Sponsored ADR’s price range in the past 12 months?
Adlai Nortye Ltd. Sponsored ADR lowest stock price was $1.85 and its highest was $17.48 in the past 12 months.
What is Adlai Nortye Ltd. Sponsored ADR’s market cap?
Adlai Nortye Ltd. Sponsored ADR’s market cap is $71.59M.
When is Adlai Nortye Ltd. Sponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Adlai Nortye Ltd. Sponsored ADR’s earnings last quarter?
Adlai Nortye Ltd. Sponsored ADR released its earnings results on Aug 08, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$1.06 by $0.71.
Is Adlai Nortye Ltd. Sponsored ADR overvalued?
According to Wall Street analysts Adlai Nortye Ltd. Sponsored ADR’s price is currently Undervalued.
Does Adlai Nortye Ltd. Sponsored ADR pay dividends?
Adlai Nortye Ltd. Sponsored ADR does not currently pay dividends.
What is Adlai Nortye Ltd. Sponsored ADR’s EPS estimate?
Adlai Nortye Ltd. Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adlai Nortye Ltd. Sponsored ADR have?
Adlai Nortye Ltd. Sponsored ADR has 93,710,810 shares outstanding.
What happened to Adlai Nortye Ltd. Sponsored ADR’s price movement after its last earnings report?
Adlai Nortye Ltd. Sponsored ADR reported an EPS of -$0.35 in its last earnings report, beating expectations of -$1.06. Following the earnings report the stock price went up 3.974%.
Which hedge fund is a major shareholder of Adlai Nortye Ltd. Sponsored ADR?
Currently, no hedge funds are holding shares in ANL
---
Adlai Nortye Ltd. Sponsored ADR Stock Smart Score
Company Description
Adlai Nortye Ltd. Sponsored ADR
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.
---
ANL Stock 12 Month Forecast
Average Price Target
$9.00
▲(363.92% Upside)
Technical Analysis
Best Analysts Covering ANL
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-20.93%
reiterated a buy rating 5 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -20.93% per trade.
---